Please login to the form below

Not currently logged in
Email:
Password:

Alapis opens veterinary companies in Serbia and Hungary

Alapis establishes two companies in Serbia and Hungary which will specialise in the production and trade of veterinary medicines and foods

Greek pharmaceutical and chemical company Alapis has established two companies, one in Serbia and another in Hungary, both of which will specialise in the production and trade of veterinary medicines and foods.

The Serbia-based operation is called Veterin Pharma Doo and has its headquarters in Beograd. The other company, based in Budapest, Hungary, is called Veterin Hungary. Alapis is the sole share holder in both companies.

Other purchasing activity
On 25 July, Alapis said that it had been selected as the highest bidder by the Serbian Privatisation Agency for the sale of a 68.3 per cent stake in pharmaceutical distribution company Sumadijalek after it bid EUR 2.2m.

Sumadijalek was founded in 1965 and had turnover of EUR 9.4m in FY05 with 48 per cent of its sales coming from pharmacies, clinics and public hospitals.

Alapis reported that negotiations would begin with the agency for the purpose of signing the contract of purchase.

In early July, Alapis revealed that it was in preliminary talks with Bayer Cropscience's local unit Bayer Hellas to acquire its pesticide plant in Viotia, Greece. As part of the transaction, Alapis said it expected to take over the production of crop chemicals in the region for Bayer.

Alapis already co-operates with Germany-headquartered Bayer on the production of veterinary drugs in Greece, Romania and Bulgaria.

1st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics